The Fort Worth Press - Revolution or mirage? Controversy surrounds new Alzheimer's drugs

USD -
AED 3.672505
AFN 64.499896
ALL 81.998222
AMD 357.803769
ANG 1.790403
AOA 917.999797
ARS 1559.233294
AUD 1.495193
AWG 1.8025
AZN 1.701015
BAM 1.782854
BBD 2.012735
BDT 124.411466
BGN 1.77347
BHD 0.377107
BIF 3003.463993
BMD 1
BND 1.288879
BOB 11.707704
BRL 5.8834
BSD 0.999385
BTN 93.383593
BWP 14.117915
BYN 2.997958
BYR 19600
BZD 2.009818
CAD 1.434097
CDF 2285.000223
CHF 0.843825
CLF 0.025578
CLP 1006.659781
CNY 6.667799
CNH 6.66677
COP 3354.45
CRC 444.296568
CUC 1
CUP 23.984575
CVE 100.51779
CZK 22.25865
DJF 177.949763
DKK 6.817398
DOP 60.418499
DZD 137.167005
EGP 53.7896
ERN 15
ETB 164.020438
EUR 0.91205
FJD 2.290495
FKP 0.76038
GBP 0.761345
GEL 2.590171
GGP 0.76038
GHS 11.732317
GIP 0.76038
GMD 73.49969
GNF 8859.697901
GTQ 7.637401
GYD 209.002981
HKD 7.84528
HNL 26.862474
HRK 6.831965
HTG 131.020966
HUF 336.577497
IDR 18262.55
ILS 3.279298
IMP 0.76038
INR 93.3316
IQD 1514.984389
IRR 1933164.499962
ISK 124.960009
JEP 0.76038
JMD 158.502846
JOD 0.709056
JPY 159.541012
KES 130.049926
KGS 87.449404
KHR 4071.103008
KMF 449.000384
KPW 900.00035
KRW 1330.895016
KWD 0.3117
KYD 0.832836
KZT 444.440393
LAK 22515.053033
LBP 89590.84067
LKR 332.58429
LRD 167.887437
LSL 17.179374
LTL 2.95274
LVL 0.60489
LYD 6.463111
MAD 9.953508
MDL 18.347645
MGA 4544.315048
MKD 56.166753
MMK 2099.801407
MNT 3600.814049
MOP 8.076574
MRU 40.612196
MUR 46.839724
MVR 15.371583
MWK 1732.793079
MXN 18.90555
MYR 4.117897
MZN 63.901745
NAD 17.179061
NGN 1350.503924
NIO 36.77352
NOK 9.71835
NPR 149.412703
NZD 1.81965
OMR 0.3845
PAB 0.999385
PEN 3.411744
PGK 4.495877
PHP 63.692991
PKR 276.292258
PLN 4.02584
PYG 6255.270079
QAR 3.643308
RON 4.876497
RSD 107.30102
RUB 82.399281
RWF 1478.922348
SAR 3.751382
SBD 8.137041
SCR 14.039055
SDG 601.499535
SEK 10.18329
SGD 1.29018
SHP 0.757117
SLE 22.800352
SLL 20969.503664
SOS 571.095199
SRD 37.384497
STD 20697.981008
STN 22.333535
SVC 8.744046
SYP 13002.000337
SZL 17.176326
THB 33.979786
TJS 9.188906
TMT 3.5
TND 3.026701
TOP 2.40776
TRY 50.462603
TTD 6.7815
TWD 32.960897
TZS 2652.99803
UAH 45.116247
UGX 4186.987794
UYU 40.602566
UZS 12002.151381
VES 916.62795
VND 25745.5
VUV 120.949122
WST 2.823281
XAF 598.265519
XAG 0.022039
XAU 0.000267920176
XCD 2.70255
XCG 1.801044
XDR 0.707052
XOF 598.265519
XPF 108.71765
YER 236.55004
ZAR 17.324306
ZMK 9001.206428
ZMW 20.525699
ZWL 321.999592
SSP 5879.599296
MXV 2.119804
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Revolution or mirage? Controversy surrounds new Alzheimer's drugs / Photo: © AFP/File

Revolution or mirage? Controversy surrounds new Alzheimer's drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

Text size:

For their defenders, the drugs lecanemab and donanemab represent the first real chance to fight the disease after decades of research -- for detractors, they are another disappointment after a long line of costly failures.

"We have turned a corner" thanks to these treatments, British biologist John Hardy, who has been studying Alzheimer's since the 1990s, told AFP.

Rob Howard, a professor of old age psychiatry at University College London, was on the other side.

"I think that the drugs have been used to raise false and unrealistic hopes in people with Alzheimer's disease and their families," he said.

These opposing statements sum up the entrenched positions on the recently introduced drugs for Alzheimer's, the most common form of dementia which millions of people across the world suffer from.

Lecanemab, sold under the name Leqembi, was developed by US pharma firms Biogen and Eisai. Donanemab, developed by pharma giant Eli Lilly, is sold as Kisunla.

The controversy has seen countries take different stances on whether to approve the drugs or not.

The United States gave the green light to lecanemab in 2023, then donanemab earlier this year.

However the European Union rejected lecanemab in July, a bad omen for donanemab's chance of approval.

Last month, the UK steered a middle course, approving the use of lecanemab but not making it available on the state National Health Service.

What no one denies is that the two drugs are the most effective Alzheimer's treatments ever -- but their effectiveness is limited.

Both appear to reduce cognitive decline in patients at the onset of their disease by around 30 percent.

While that may seem high, it represents a relatively small difference over the year-and-a-half period when the studies were carried out.

"The benefits are so tiny as to be practically invisible in an individual patient," Howard said.

- Exorbitant cost -

For critics, there are not enough benefits to outweigh the risks of the drugs, which can sometimes cause brain swelling or bleeding that in rare cases has proved fatal.

And they are very expensive. At the prices being charged by Biogen and Eisai in the United States, lecanemab would cost 133 billion euros ($148 billion) if given to all eligible patients in the EU, according to a 2023 study.

Advocates of the drugs, including many neurologists, believe they can offer patients a few more precious months of autonomy.

They also believe that the effectiveness of the drugs could be multiplied if patients started taking them earlier in the disease's progression. This could soon be more practicable as research on diagnosing Alzheimer's more quickly has recently been making significant strides.

The differing national policies could also mean that poorer patients are left behind.

"We will see rich people going to the US" for the drugs, Hardy said.

The debate can be traced back in part to a seminal 1992 article by Hardy about how the disease actually works.

The article argues that clumps of protein called amyloid plaques -- a constant in the brains of Alzheimer's patients -- are not just one element among others, but the main factor triggering the disease.

Over the decades, many drugs targeting these amyloid plaques were developed, all of which failed -- until lecanemab and donanemab.

- Pressure from families -

The scepticism from some quarters about the new drugs could be because the previous ones were defended and even lauded by some, despite their ineffectiveness.

Christian Guy-Coichard, the head of French organisation Formindep which monitors medical conflicts of interest, accused Alzheimer's groups, researchers and pharmaceutical firms of being too close.

But France Alzheimer deputy director Benoit Durand said that very little of its funding came from Biogen/Eisai or Eli Lilly, instead pointing towards pressure for new treatments from patients' families.

"They don't understand" the EU's decision to turn down a breakthrough new drug, Durand told AFP. He also feared that laboratories could lose interest in Alzheimer's disease due to the setbacks.

Even within the pharmaceutical industry, some admit that past failures have not necessarily helped build trust.

A doctor working for Eli Lilly, who spoke on condition of anonymity, blamed its rival Biogen for overstating the benefits of previous treatment Aduhelm. The drug was controversially approved in the US in 2021 before being withdrawn.

"The Aduhelm studies were a mess," the doctor said.

The aftermath "did a lot of harm and sowed chaos in the discipline", the doctor added, pointing the finger at Biogen.

In response, Biogen told AFP that it was complying with "the principles of scientific research as well as legal and regulatory requirements".

But the Eli Lilly doctor defended the new treatments all the same, urging people to look to the future, not the past.

Like other specialists, he also acknowledged that other mechanisms besides amyloids that could be behind Alzheimer's need to be explored.

Given the disease's complexity, it is unlikely that "single-target treatments will achieve substantially larger effects" than lecanemab and donanemab, a group of experts wrote in the Journal of Prevention of Alzheimer's Disease last month.

But the new drugs are a "critical step" in Alzheimer's treatment, they added.

S.Weaver--TFWP